Medarex, Inc. today announced the advancement by Novartis Pharma AG (Novartis) of ACZ885, a fully human anti-IL1 beta antibody, into a Phase III clinical trial for Muckle Wells Syndrome
PRINCETON, NJ, USA | July 18, 2007 | Medarex, Inc. (Nasdaq: MEDX) today announced the advancement by Novartis Pharma AG (Novartis) of ACZ885, a fully human anti-IL1 beta antibody, into a Phase III clinical trial for Muckle Wells Syndrome. As a result of such advancement, Medarex expects to receive an undisclosed milestone payment from its licensing partner, Novartis. The antibody was generated using Medarex’s UltiMAb(R) technology as part of the collaboration with Novartis. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and achieve commercial sales.
"This milestone represents the seventh UltiMAb antibody to move into Phase III clinical development. We are pleased with this advancement and hope to see the continued progress of this antibody," said Howard H. Pien, President and CEO of Medarex.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Novartis’ activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex’s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex’s public disclosure filings are available from its investor relations department. Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
SOURCE: Medarex, Inc.
Post Views: 125
Medarex, Inc. today announced the advancement by Novartis Pharma AG (Novartis) of ACZ885, a fully human anti-IL1 beta antibody, into a Phase III clinical trial for Muckle Wells Syndrome
PRINCETON, NJ, USA | July 18, 2007 | Medarex, Inc. (Nasdaq: MEDX) today announced the advancement by Novartis Pharma AG (Novartis) of ACZ885, a fully human anti-IL1 beta antibody, into a Phase III clinical trial for Muckle Wells Syndrome. As a result of such advancement, Medarex expects to receive an undisclosed milestone payment from its licensing partner, Novartis. The antibody was generated using Medarex’s UltiMAb(R) technology as part of the collaboration with Novartis. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and achieve commercial sales.
"This milestone represents the seventh UltiMAb antibody to move into Phase III clinical development. We are pleased with this advancement and hope to see the continued progress of this antibody," said Howard H. Pien, President and CEO of Medarex.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Novartis’ activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex’s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex’s public disclosure filings are available from its investor relations department. Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
SOURCE: Medarex, Inc.
Post Views: 125
